Clinical trials: Atrophy of Vagina
Sexual Pain Disorders, Postmenopausal Symptoms
Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment
This study will evaluate the use of topical 5 or 10% sinecatechins, a botanical drug derived from green tea for the alleviation of sexual pain in the area around the vaginal opening (the vulvar vestibule), that is a main source…
- Conditions
- Sexual Pain Disorders, Postmenopausal Symptoms, Vulvovaginal Atrophy, Female Sexual Dysfunction
- Trial name
- NCT03682601
- Testing
- 5% sinecatechins ointment, 10% sinecatechins ointment
- Where
- 4 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GTO Pharmaceutical, LLC
Genitourinary Syndrome of Menopause, Vaginal Atrophy
Vaginal Laser Therapy in Breast Cancer Survivors
This study evaluates the efficacy of vaginal CO2 laser therapy in breast cancer survivors with symptoms of Genitourinary Syndrome of Menopause.
- Conditions
- Genitourinary Syndrome of Menopause, Vaginal Atrophy, Breast Cancer, Dyspareunia
- Trial name
- NCT03738605
- Testing
- Microablative Fractional CO2 Laser Therapy
- Where
- Greece
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Vaginal Atrophy, Vaginal Relaxation
Evaluation of Efficacy and Safety of Votiva for Vaginal Rejuvenation
This is a multi-site, randomized, prospective study designed to evaluate the safety and efficacy of the Votiva device headpieces through radiofrequency for vaginal rejuvenation.
- Conditions
- Vaginal Atrophy, Vaginal Relaxation, Stress Urinary Incontinence
- Trial name
- NCT03520426
- Testing
- Votiva RF
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Walden, Jennifer L., M.D.,P.L.L.C.
Vulvar and Vaginal Atrophy
To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.
This is a Randomized, Parallel-Group, Placebo- Controlled, Multicenter Study to Evaluate the Therapeutic Equivalence and Safety of Estradiol Vaginal Tablets 10 mcg and Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk…
- Trial name
- NCT02668796
- Testing
- Estradiol Vaginal Tablets 10 mcg (Glenmark), Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)
- Where
- United States
- Volunteers
- 522 people, healthy volunteers welcome
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Vaginal Atrophy
A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin
This study aims to evaluate the uptake of oxytocin following intravaginal administration of Vagitocin 400IU over a period of 15 days and also to compare oxytocin bioavailability after vaginal and intravenous administration.
- Trial name
- NCT01975129
- Testing
- Vagitocin
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- PepTonic Medical AB
Vaginal Atrophy
A Clinical Clinical Observation of CO2 Fractional Laser in Female Vaginal Repair
1. Vaginal atrophy is the most common indication in the treatment of vaginal rejuvenation. Its main manifestation is vaginal relaxation syndrome, which may be the early symptom of female pelvic floor dysfunction.
- Trial name
- NCT04492176
- Testing
- CO2 fractional laser（ACUPULSE,Lumenis）
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Vaginal Atrophy
A Randomized Controlled Phase 2 Study to Determine Lowest Efficacious Dose of Ovestin in Vulvar and Vaginal Atrophy
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, dose-de-escalation study whose purpose is to establish the lowest efficacious dose.
- Trial name
- DOVE (NCT04159493)
- Testing
- Estriol
- Volunteers
- healthy volunteers welcome
- Sponsor
- Aspen USA Inc
Atrophy, Vaginal Atrophy
Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects
The purpose of this study is to assess the use of the Alma CO2 Pixel FemiLift™ in the treatment of VulvoVaginal Atrophy (VVA) in postmenopausal female subjects.
- Conditions
- Atrophy, Vaginal Atrophy, Genital Diseases, Female
- Trial name
- NCT02747641
- Testing
- Pixel CO2 Laser System
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Alma Lasers Inc.
Pelvic Organ Prolapse, Urinary Incontinence
Vaginal Estradiol Use in Pessary Care
The primary outcome of this study compare the rate of pessary discontinuation at 6 months post-pessary fitting in women using vaginal estradiol versus those not using vaginal estradiol.
- Conditions
- Pelvic Organ Prolapse, Urinary Incontinence, Pessary Ulcer of Vagina, Vaginal Atrophy
- Trial name
- NCT05458375
- Testing
- Estradiol vaginal cream
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Menopause
The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health
This Phase II study is designed to evaluate the potential effects of a novel probiotic supplement on the severity of global menopause symptoms (e.g., psychological, somatic, urogenital symptoms) and on bone health in…
- Trial name
- MPS (NCT04001088)
- Testing
- Probiotic
- Where
- 5 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions
Dyspareunia
Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors
This trial seeks to determine if therapy with a CO2 laser to the vagina is more effective than lidocaine to the opening of the vagina before intercourse to reduce painful intercourse in women who are breast cancer survivors.
- Trial name
- BCLS (NCT03257670)
- Testing
- 4% Topical Lidocaine Gel, CO2RE fractional laser therapy
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
Genitourinary Agents
Genetic Aspects of Vaginal Aging
Life expectancy depends on a number of different factors, of which only about 20-30% are genetically determined. The overwhelming majority are non-genetic determinants.
- Trial name
- NCT05318989
- Where
- Poland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Żelazna Medical Centre, LLC
Vaginal Atrophy
Investigation of Efficacy and Tolerability of WO 2707, a MoistCream Cremolum, in Postmenopausal Women Suffering From Symptoms of Vaginal Dryness
The objective of the clinical investigation is to evaluate the efficacy and tolerability of WO 2707, a MoistCream Cremolum, with respect to the application in postmenopausal women with symptoms of vaginal dryness.
- Trial name
- NCT05211505
- Testing
- WO 2707
- Where
- Germany
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Vulvovaginal Atrophy, Menopause
Multi-polar RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity
The study evaluates the use of multi-polar radiofrequency (RF) and pulsed electro-magnetic fields (PEMF) energies for the treatment of vaginal looseness and for the treatment of the mons pubis and labia for skin tightening.
- Conditions
- Vulvovaginal Atrophy, Menopause, Menopause Surgical
- Trial name
- NCT03536585
- Testing
- Vulvovaginal treatment, Baseline
- Where
- 3 sites in Canada
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Venus Concept
Vaginal Atrophy
Clinical Evaluation of Fractional Bi-Polar Radio-Frequency for Symptoms of Vulvovaginal Atrophy
Prospective, one arm, baseline-controlled At least 30 healthy adult female volunteers, from 2 investigational sites seeking treatment for Symptoms of Vulvovaginal Atrophy Eligible subjects will receive 3 treatments 4 weeks apart…
- Trial name
- NCT05398172
- Testing
- MorpheusV Applicator
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- InMode MD Ltd.
Menopause, Vaginal Atrophy
CO2 Laser in the Treatment of the GSM - (Genitourinary Syndrome of Menopause) Genitourinary Syndrome of Menopause
Menopause is a woman's hormonal status one year after her ovulatory failure, when the decrease of circulating estrogen levels leads to a group of symptoms named Genitourinary Syndrome of Menopause (GSM), such as: vaginal dryness…
- Conditions
- Menopause, Vaginal Atrophy, Urinary Incontinence
- Trial name
- NCT03939078
- Testing
- CO2 fractional ablative laser
- Where
- Brazil
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Universidade Federal Fluminense
Vulvovaginal Atrophy
Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream
Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream in postmenopausal women aged 45 years or older, with one or more moderate to severe symptoms of vulvovaginal…
- Trial name
- NCT04232813
- Testing
- Estradiol 10 MCG Vaginal Tablet [VAGIFEM], Promestriene Vaginal
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Instituto Palacios
Vaginal Atrophy
Vaginal CO2 Laser and the Genitourinary Syndrome of Menopause
This study evaluates the clinical, histopathological, cytological and microbiological efficacy of Microablative Fractional CO2 laser intravaginally administered in postmenopausal women with Genitourinary Syndrome of Menopause.
- Trial name
- NCT03754205
- Testing
- Microablative Fractional CO2 laser
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Vaginal Atrophy, Genitourinary System; Disorder, Female
A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment Outcomes
The focus of this study is to assess breast cancer survivors perspectives of Viveve® Treatment using patient reported outcome tools with a focus on symptoms associated with vulvovaginal atrophy/genitourinary syndrome of menopause…
- Conditions
- Vaginal Atrophy, Genitourinary System; Disorder, Female, Vaginal Abnormality, Sexual Dysfunction
- Trial name
- BRAVO (NCT03547089)
- Testing
- Viveve®
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- W. Grant Stevens, MD
Recurrent Urinary Tract Infection, Vaginal Atrophy
Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo
Women over the age of 60 years have an estimated 10 to 15 % risk of recurrent urinary tract infections (UTI). This is believed to be due to hormonally induced changes in the vaginal flora associated with menopause.
- Conditions
- Recurrent Urinary Tract Infection, Vaginal Atrophy, Postmenopausal Disorder
- Trial name
- PIVoT (NCT04807894)
- Testing
- Vaginal Cream with Applicator
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Jefferson Drapkin